Pifithrin-alpha-HBr, p53 Inhibitor (ab120478)
Key features and details
- p53 Inhibitor
- CAS Number: 63208-82-2
- Soluble in DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
Pifithrin-alpha-HBr, p53 Inhibitor -
Description
p53 Inhibitor -
General notes
Pifithrin-?-HBr is light senstive and it is recommended that the compound is protected from light.
-
CAS Number
63208-82-2 -
Chemical structure
Properties
-
Chemical name
1-(4-Methylphenyl)-2-(4,5,6,7-tetrahydro-2-imino-3(2H)-benzothiazolyl)ethanone hydrobromide -
Molecular weight
367.30 -
Molecular formula
C16H18N2OS.HBr -
PubChem identifier
9929138 -
Storage instructions
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in DMSO to 100 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
Br.Cc1ccc(cc1)C(=O)CN2C=3CCCCC=3SC2=N -
Source
Synthetic
-
Research areas
Images
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (4)
ab120478 has been referenced in 4 publications.
- Jia J et al. Transcriptional factor FoxM1-activated microRNA-335-3p maintains the self-renewal of neural stem cells by inhibiting p53 signaling pathway via Fmr1. Stem Cell Res Ther 12:169 (2021). PubMed: 33691791
- Zhan H et al. Downregulation of miR-128 Ameliorates Ang II-Induced Cardiac Remodeling via SIRT1/PIK3R1 Multiple Targets. Oxid Med Cell Longev 2021:8889195 (2021). PubMed: 34646427
- Uehara M et al. Pharmacological inhibition of ataxia-telangiectasia mutated exacerbates acute kidney injury by activating p53 signaling in mice. Sci Rep 10:4441 (2020). PubMed: 32157166
- Li S et al. Synergistic anticancer effect of combined crocetin and cisplatin on KYSE-150 cells via p53/p21 pathway. Cancer Cell Int 17:98 (2017). PubMed: 29093644